Yes, absolutely test for tuberculosis in addition to the malignancy workup
In a patient with prior TB history presenting with peritoneal fluid showing isolated signet-ring cells and prominent lymphocytes, you must simultaneously pursue both tuberculosis testing (ADA, TB PCR, AFB culture) and the planned immunohistochemistry/cell-block evaluation for ovarian carcinoma. Your relative's suggestion to add ADA testing is clinically sound and should be implemented immediately.
Why Both Diagnoses Must Be Pursued Simultaneously
The Clinical Picture Strongly Suggests TB
The cytologic findings you describe—isolated signet-ring cells without 2D/3D clusters plus abundant lymphocytes—are actually more consistent with tuberculous peritonitis than peritoneal carcinomatosis:
- Lymphocyte-predominant ascites (especially >60-70% lymphocytes) is characteristic of TB peritonitis 1, 2
- Low mesothelial cell count (<1%) combined with lymphocyte predominance is a supportive clue for TB 2
- Isolated malignant cells without clusters can occur in TB mimicking malignancy 3, 4
- The prior TB history dramatically increases pretest probability 1, 5
TB and Malignancy Can Coexist
Critically, approximately 5% of patients with ascites have two simultaneous causes (so-called "mixed ascites"), commonly cirrhosis plus peritoneal carcinomatosis or TB 5. In immunocompromised or oncologic patients, TB can develop alongside or mimic malignancy 3, 6.
Specific Tests to Order Immediately
Essential TB Testing on Peritoneal Fluid:
Adenosine Deaminase (ADA) - Most important test
TB PCR/NAAT (nucleic acid amplification test)
AFB smear and mycobacterial culture
Cell count with differential
- Document lymphocyte percentage and mesothelial cell proportion 2
Continue Planned Malignancy Workup:
- Cell block preparation for adequate tissue 11
- Immunohistochemistry panel including WT1, p53, PAX8, CA125 for ovarian carcinoma typing 12, 11
- Ensure ≥30% tumor cells in specimen for molecular testing 11
Critical Diagnostic Algorithm
Step 1: Order ADA on the fluid immediately
- If ADA ≥27 IU/L → High probability TB, start anti-TB therapy while awaiting culture
- If ADA <22.5 IU/L → TB essentially excluded, focus on malignancy workup
Step 2: Interpret tumor markers in context
- Elevated ascitic CEA (>3.65 ng/mL), CA15-3 (>42.7 U/mL), or CA19-9 (>25.1 U/mL) favor malignancy 7
- Combined positive tumor markers + ADA <22.5 IU/L has 100% specificity for peritoneal carcinomatosis 7
- However, serum CA-125 is nonspecific and elevated in both TB and malignancy 5, 10
Step 3: If both tests inconclusive
- Consider laparoscopic peritoneal biopsy with histopathology and mycobacterial culture—this is the gold standard when fluid analysis is nondiagnostic 1, 9, 6, 10
Common Pitfalls to Avoid
Do not rely on cytology alone - Signet-ring-like cells can occur in TB inflammation mimicking adenocarcinoma 3, 4
Do not skip ADA testing - It is the single most useful discriminator between TB and malignancy in peritoneal fluid 9, 7, 8
Do not assume elevated CA-125 means cancer - This marker is elevated in any cause of ascites including TB 5, 10
Do not wait for culture results - They take 4-8 weeks; use ADA and PCR for rapid decision-making 9, 6
Do not dismiss TB based on negative AFB smear - Sensitivity is extremely low (0-86%) 1, 5
The Bottom Line
The combination of prior TB history + lymphocyte-predominant ascites + isolated atypical cells creates diagnostic ambiguity that cannot be resolved by malignancy workup alone. Missing TB peritonitis has devastating consequences (progressive disease, death) while missing early ovarian cancer is equally serious. The ADA test costs little, provides results within 24-48 hours, and has excellent diagnostic accuracy 9, 7, 8. There is no justification for omitting it.
Your relative's clinical instinct is correct—add ADA testing now 1, 9.